Preclinical development of neur-04, a novel anticonvulsant

Neuractas Therapeutics is a Canadian pharmaceutical company that is developing novel agents for neurological indications. Neuractas has developed neur-04 for epilepsy, this agent is a reformulation of an existing drug that has demonstrated strong clinical anticonvulsant activity in the most difficult-to-treat cases of epilepsy. Often people with epilepsy have to try several different medications before they find one that works. This study will test neur-04 on brain cells in a laboratory setting to determine which types of epilepsy may benefit most from neur-04 so patients can be properly selected to use it. Neur-04 will also be combined with other existing anticonvulsant drugs to find drugs that it can be paired with to have the best effect.

Faculty Supervisor:

Peter Carlen

Student:

Partner:

Neuractas Therapeutics

Discipline:

Life Sciences

Sector:

Manufacturing

University:

University Health Network; University of Toronto

Program: